UM

Browse/Search Results:  1-10 of 37 Help

Filters    
Selected(0)Clear Items/Page:    Sort:
Mitochondrial protective effect of neferine through the modulation of nuclear factor erythroid 2-related factor 2 signalling in ischaemic stroke Journal article
BRITISH JOURNAL OF PHARMACOLOGY, 2019,Volume: 176,Issue: 3,Page: 400-415
Authors:  Chuanhong Wu;  Jianxin Chen;  Ruocong Yang;  Feipeng Duan;  Shaojing Li;  Xiuping Chen
Favorite  |  View/Download:13/0  |  Submit date:2020/01/07
A novel Ca2+ current blocker promotes angiogenesis and cardiac healing after experimental myocardial infarction in mice Journal article
PHARMACOLOGICAL RESEARCH, 2018,Volume: 134,Page: 109-117
Authors:  Cui, Guozhen;  Xin, Qiqi;  Tseng, Hisa Hui Ling;  Hoi, Maggie PuiMan;  Wang, Yan;  Yang, Binrui;  Choi, InLeng;  Wang, Yuqiang;  Yuan, Rong;  Chen, Keji;  Cong, Weihong;  Lee, Simon MingYuen
View  |  Adobe PDF(3018Kb)  |  Favorite  |  View/Download:355/13  |  Submit date:2018/10/30
Cardioprotection  Angiogenesis  ADTM  Zebrafish  VEGF  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
MOLECULAR NEUROBIOLOGY, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo, Dan;  Zhao, Jia;  Cheng, Yuanyuan;  Lee, Simon Ming-Yuen;  Rong, Jianhui
Favorite  |  View/Download:11/0  |  Submit date:2018/10/30
Parkinson's disease  Neuroprotection  N-propargyl caffeamide (PACA)  NGF/TrkApathway  PI3K/Akt  ERK1/2  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
MOLECULAR NEUROBIOLOGY, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo, Dan;  Zhao, Jia;  Cheng, Yuanyuan;  Lee, Simon Ming-Yuen;  Rong, Jianhui
Favorite  |  View/Download:10/0  |  Submit date:2018/10/31
Parkinson's disease  Neuroprotection  N-propargyl caffeamide (PACA)  NGF/TrkApathway  PI3K/Akt  ERK1/2  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
MOLECULAR NEUROBIOLOGY, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo, Dan;  Zhao, Jia;  Cheng, Yuanyuan;  Lee, Simon Ming-Yuen;  Rong, Jianhui
Favorite  |  View/Download:16/0  |  Submit date:2018/10/31
Parkinson's disease  Neuroprotection  N-propargyl caffeamide (PACA)  NGF/TrkApathway  PI3K/Akt  ERK1/2  
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF Journal article
MOLECULAR NEUROBIOLOGY, 2018,Volume: 55,Issue: 3,Page: 2258-2267
Authors:  Luo, Dan;  Zhao, Jia;  Cheng, Yuanyuan;  Lee, Simon Ming-Yuen;  Rong, Jianhui
Favorite  |  View/Download:9/0  |  Submit date:2018/10/30
Parkinson's disease  Neuroprotection  N-propargyl caffeamide (PACA)  NGF/TrkApathway  PI3K/Akt  ERK1/2  
Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells Journal article
SCIENTIFIC REPORTS, 2018,Volume: 8
Authors:  Wu, Chuanhong;  Zhao, Wenwen;  Yu, Jie;  Li, Shaojing;  Lin, Ligen;  Chen, Xiuping
Favorite  |  View/Download:21/0  |  Submit date:2018/10/30
Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B Journal article
NEUROPHARMACOLOGY, 2017,Volume: 126,Page: 12-24
Authors:  Guo, Baojian;  Hu, Shengquan;  Zheng, Chengyou;  Wang, Hongyu;  Luo, Fangcheng;  Li, Haitao;  Cui, Wei;  Yang, Xifei;  Cui, Guozhen;  Mak, Shinghung;  Choi, Tony Chung-Lit;  Ma, Edmond Dik-Lung;  Wang, Yuqiang;  Lee, Simon Ming Yuen;  Zhang, Zaijun;  Han, Yifan
View  |  Adobe PDF(2766Kb)  |  Favorite  |  View/Download:362/9  |  Submit date:2018/10/31
Parkinson's disease  SU4312  Neuroprotection  Myocyte enhancer factor 2D  Monoamine oxidase-B  
Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B Journal article
NEUROPHARMACOLOGY, 2017,Volume: 126,Page: 12-24
Authors:  Guo, Baojian;  Hu, Shengquan;  Zheng, Chengyou;  Wang, Hongyu;  Luo, Fangcheng;  Li, Haitao;  Cui, Wei;  Yang, Xifei;  Cui, Guozhen;  Mak, Shinghung;  Choi, Tony Chung-Lit;  Ma, Edmond Dik-Lung;  Wang, Yuqiang;  Lee, Simon Ming Yuen;  Zhang, Zaijun;  Han, Yifan
Favorite  |  View/Download:20/0  |  Submit date:2018/10/30
Parkinson's disease  SU4312  Neuroprotection  Myocyte enhancer factor 2D  Monoamine oxidase-B  
Artemisinin conferred ERK-mediated neuroprotection to PC12 cells and cortical neurons exposed to sodium nitroprusside-induced oxidative insult Conference paper
Authors:  Zheng, W.;  Lazarovici, P.
Favorite  |  View/Download:4/0  |  Submit date:2018/10/30